tradingkey.logo


ADMA Biologics Inc

ADMA

20.088USD

+0.758+3.92%
āđ€āļ§āļĨāļēāļ—āļģāļāļēāļĢāļ•āļĨāļēāļ” ETāļĢāļēāļ„āļēāļĨāđˆāļēāļŠāđ‰āļē 15 āļ™āļēāļ—āļĩ
4.79BāļĄāļđāļĨāļ„āđˆāļēāļ•āļĨāļēāļ”
23.17P/E TTM

āļĢāļēāļĒāļĨāļ°āđ€āļ­āļĩāļĒāļ”āđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ‚āļ­āļ‡ ADMA Biologics Inc āļšāļĢāļīāļĐāļąāļ—
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: BIVIGAM (immune globulin intravenous, human) for the treatment of primary humoral immunodeficiency (PI); ASCENIV (immune globulin intravenous, human - slra 10% liquid) for the treatment of PI, and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
āļ‚āđ‰āļ­āļĄāļđāļĨāļšāļĢāļīāļĐāļąāļ—
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ADMA
āļŠāļ·āđˆāļ­āļšāļĢāļīāļĐāļąāļ—ADMA Biologics Inc
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļOct 17, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Adam S. Grossman
āļˆāļģāļ™āļ§āļ™āļžāļ™āļąāļāļ‡āļēāļ™677
āļ›āļĢāļ°āđ€āļ āļ—āļāļēāļĢāļĢāļąāļāļĐāļēāļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒOrdinary Share
āļŠāļīāđ‰āļ™āļ›āļĩāļ‡āļšāļ›āļĢāļ°āļĄāļēāļ“Oct 17
āļ—āļĩāđˆāļ­āļĒāļđāđˆ465 State Route 17
āđ€āļĄāļ·āļ­āļ‡RAMSEY
āļ•āļĨāļēāļ”āļŦāļĨāļąāļāļ—āļĢāļąāļžāļĒāđŒNASDAQ Global Market Consolidated
āļ›āļĢāļ°āđ€āļ—āļĻUnited States of America
āļĢāļŦāļąāļŠāđ„āļ›āļĢāļĐāļ“āļĩāļĒāđŒ07446
āđ‚āļ—āļĢāļĻāļąāļžāļ—āđŒ12014785552
āđ€āļ§āđ‡āļšāđ„āļ‹āļ•āđŒhttps://www.admabiologics.com/
āļŠāļąāļāļĨāļąāļāļĐāļ“āđŒāļĒāđˆāļ­āļ‚āļ­āļ‡āļŦāļļāđ‰āļ™ADMA
āļ§āļąāļ™āļ—āļĩāđˆāđ€āļŠāļ™āļ­āļ‚āļēāļĒāļ„āļĢāļąāđ‰āļ‡āđāļĢāļOct 17, 2013
āļ‹āļĩāļ­āļĩāđ‚āļ­Mr. Adam S. Grossman
āļœāļđāđ‰āļšāļĢāļīāļŦāļēāļĢāļšāļĢāļīāļĐāļąāļ—
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.76M
-0.16%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
570.90K
--
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
258.17K
-2.68%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
145.83K
-12.06%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
--
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
--
Dr. Young T. Kwon, Ph.D.
Dr. Young T. Kwon, Ph.D.
Independent Director
Independent Director
--
--
Ms. Alison C. Finger
Ms. Alison C. Finger
Independent Director
Independent Director
--
--
Ms. Kaitlin Kestenberg
Ms. Kaitlin Kestenberg
Chief Operating Officer, Senior Vice President - Compliance
Chief Operating Officer, Senior Vice President - Compliance
--
--
āļŠāļ·āđˆāļ­
āļŠāļ·āđˆāļ­/āļ•āļģāđāļŦāļ™āđˆāļ‡
āļ•āļģāđāļŦāļ™āđˆāļ‡
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
Mr. Adam S. Grossman
Mr. Adam S. Grossman
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
3.76M
-0.16%
Dr. Jerrold B. Grossman
Dr. Jerrold B. Grossman
Vice Chairman of the Board, Co-Founder
Vice Chairman of the Board, Co-Founder
570.90K
--
Mr. Brad L. Tade
Mr. Brad L. Tade
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
258.17K
-2.68%
Mr. Lawrence P. Guiheen
Mr. Lawrence P. Guiheen
Independent Director
Independent Director
145.83K
-12.06%
Mr. Steven A. (Steve) Elms
Mr. Steven A. (Steve) Elms
Independent Chairman of the Board
Independent Chairman of the Board
87.33K
--
Mr. Eduardo Rene Salas
Mr. Eduardo Rene Salas
Independent Director
Independent Director
10.89K
--
āļŠāļąāļ”āļŠāđˆāļ§āļ™āļ‚āļ­āļ‡āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
āļŠāļāļļāļĨāđ€āļ‡āļīāļ™: USDāļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļēāļ—āļīāļ•āļĒāđŒāļ—āļĩāđˆ 6 āļ.āļ„.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„USD
āļŠāļ·āđˆāļ­
āļĢāļēāļĒāđ„āļ”āđ‰
āļŠāļąāļ”āļŠāđˆāļ§āļ™
United States
110.73M
96.45%
International
4.07M
3.55%
āļ•āļēāļĄāļ˜āļļāļĢāļāļīāļˆ
āļ•āļēāļĄāļ āļđāļĄāļīāļ āļēāļ„
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļŠāļ–āļīāļ•āļīāļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 17 āļž.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 17 āļž.āļ„.
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
14.32%
The Vanguard Group, Inc.
8.95%
State Street Global Advisors (US)
4.79%
Invesco Advisers, Inc.
4.06%
Geode Capital Management, L.L.C.
2.37%
Other
65.50%
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
BlackRock Institutional Trust Company, N.A.
14.32%
The Vanguard Group, Inc.
8.95%
State Street Global Advisors (US)
4.79%
Invesco Advisers, Inc.
4.06%
Geode Capital Management, L.L.C.
2.37%
Other
65.50%
āļ›āļĢāļ°āđ€āļ āļ—āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Investment Advisor
48.40%
Investment Advisor/Hedge Fund
29.25%
Hedge Fund
7.14%
Research Firm
3.34%
Individual Investor
2.56%
Private Equity
1.47%
Pension Fund
1.25%
Bank and Trust
0.42%
Sovereign Wealth Fund
0.24%
Other
5.92%
āļāļēāļĢāļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ‚āļ­āļ‡āļŠāļ–āļēāļšāļąāļ™î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āļ­āļąāļ‡āļ„āļēāļĢāļ—āļĩāđˆ 1 āļ.āļ„.
āļŠāđˆāļ§āļ‡āđ€āļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļ‡āļēāļ™
āļˆāļģāļ™āļ§āļ™āļŠāļ–āļēāļšāļąāļ™
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
2025Q2
673
224.65M
94.10%
-5.98M
2025Q1
658
218.51M
91.53%
-12.93M
2024Q4
607
216.39M
91.46%
-18.31M
2024Q3
547
221.08M
93.58%
+11.33M
2024Q2
451
193.54M
83.08%
-7.68M
2024Q1
408
187.57M
81.05%
-5.26M
2023Q4
371
181.77M
80.46%
-8.48M
2023Q3
362
185.07M
81.97%
+86.17K
2023Q2
349
179.85M
80.15%
-7.63M
2023Q1
335
188.11M
85.60%
+12.05M
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
āļāļīāļˆāļāļĢāļĢāļĄāļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™î™Œ
āļŠāļ·āđˆāļ­
āļŦāļļāđ‰āļ™āļ—āļĩāđˆāļ–āļ·āļ­āļ„āļĢāļ­āļ‡
āļŠāļąāļ”āļŠāđˆāļ§āļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™
āđ€āļ›āļĨāļĩāđˆāļĒāļ™%
āļ§āļąāļ™āļ—āļĩāđˆ
BlackRock Institutional Trust Company, N.A.
34.20M
14.32%
-829.83K
-2.37%
Mar 31, 2025
The Vanguard Group, Inc.
16.79M
7.03%
-1.36M
-7.48%
Mar 31, 2025
State Street Global Advisors (US)
11.44M
4.79%
-3.43M
-23.07%
Mar 31, 2025
Invesco Advisers, Inc.
9.69M
4.06%
+483.20K
+5.25%
Mar 31, 2025
Geode Capital Management, L.L.C.
5.67M
2.37%
+235.43K
+4.33%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
4.86M
2.04%
+191.99K
+4.11%
Mar 31, 2025
Two Sigma Investments, LP
4.84M
2.03%
-657.17K
-11.95%
Mar 31, 2025
American Century Investment Management, Inc.
4.25M
1.78%
+478.80K
+12.69%
Mar 31, 2025
Morgan Stanley & Co. LLC
4.17M
1.75%
-641.18K
-13.33%
Mar 31, 2025
Grossman (Adam S)
3.77M
1.58%
-6.00K
-0.16%
Jun 16, 2025
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
ETF āļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡î™Œ
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļ­āļąāļ›āđ€āļ”āļ•āđ€āļĄāļ·āđˆāļ­: āļ§āļąāļ™āđ€āļŠāļēāļĢāđŒāļ—āļĩāđˆ 2 āļŠ.āļ„.
āļŠāļ·āđˆāļ­
āļŠāļąāļ”āļŠāđˆāļ§āļ™
Simplify Health Care ETF
5.3%
AAM Sawgrass US Small Cap Quality Growth ETF
3.58%
Invesco S&P SmallCap Health Care ETF
3.11%
Alpha Architect U.S. Quantitative Momentum ETF
1.74%
Virtus LifeSci Biotech Products ETF
1.62%
Invesco S&P SmallCap Momentum ETF
1.62%
Invesco S&P SmallCap Quality ETF
1.44%
Invesco S&P SmallCap 600 Pure Growth ETF
1.36%
SPDR S&P Biotech ETF
1.23%
First Trust Active Factor Small Cap ETF
0.93%
āļ”āļđāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄ
Simplify Health Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™5.3%
AAM Sawgrass US Small Cap Quality Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.58%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™3.11%
Alpha Architect U.S. Quantitative Momentum ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.74%
Virtus LifeSci Biotech Products ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.62%
Invesco S&P SmallCap Momentum ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.62%
Invesco S&P SmallCap Quality ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.44%
Invesco S&P SmallCap 600 Pure Growth ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.36%
SPDR S&P Biotech ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™1.23%
First Trust Active Factor Small Cap ETF
āļŠāļąāļ”āļŠāđˆāļ§āļ™0.93%
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļĄāļĩāļāļēāļĢāļˆāđˆāļēāļĒāđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨāđ€āļ›āđ‡āļ™āļˆāļģāļ™āļ§āļ™āļĢāļ§āļĄ 0.00 USD āđƒāļ™āļŠāđˆāļ§āļ‡ 5 āļ›āļĩāļ—āļĩāđˆāļœāđˆāļēāļ™āļĄāļē
āļ§āļąāļ™āļ—āļĩāđˆ
āđ€āļ‡āļīāļ™āļ›āļąāļ™āļœāļĨ
āļ§āļąāļ™āļ—āļĩāđˆāļšāļąāļ™āļ—āļķāļ
āļ§āļąāļ™āļ—āļĩāđˆāļŠāļģāļĢāļ°āđ€āļ‡āļīāļ™
āļ§āļąāļ™āļ—āļĩāđˆāđ„āļĄāđˆāđ„āļ”āđ‰āļĢāļąāļšāļŠāļīāļ—āļ˜āļīāļ›āļąāļ™āļœāļĨ
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļāļēāļĢāđāļšāđˆāļ‡āļŦāļļāđ‰āļ™î™Œ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
āļ§āļąāļ™āļ—āļĩāđˆ
āļ›āļĢāļ°āđ€āļ āļ—
āļ­āļąāļ•āļĢāļēāļŠāđˆāļ§āļ™
āđ„āļĄāđˆāļĄāļĩāļ‚āđ‰āļ­āļĄāļđāļĨ
KeyAI
î™